Reliant AI Emerges from Stealth with $11.3M for GenAI Biopharma Data Analysis

Reliant AI Emerges from Stealth with $11.3M for Biopharma Data Analysis

What You Should Know: 

Reliant AI, a provider of generative AI-powered data analytics software, today announced its official launch and a significant $11.3M in seed funding round led by Tola Capital and Inovia Capital, with participation from angel investor Mike Volpi, the investment will fuel the company’s growth and expansion.

– Founded by a team of leading experts in natural language processing and reinforcement learning with backgrounds at DeepMind, Google Brain, and EY Parthenon, Reliant AI is committed to harnessing the power of generative AI to address complex information challenges in the enterprise. The company’s initial focus is on the biopharmaceutical industry, where data-driven insights are crucial for accelerating drug discovery and development.

Reliant AI’s flagship product, Reliant Tabular, is an AI workbench designed to streamline the process of finding scientific evidence for decision-making. By automating systematic reviews, asset scans, and comprehensive analyses, Reliant Tabular empowers life science analysts to focus on higher-value tasks. The platform’s unique features include:

  • Proprietary ML models: Optimized for biopharma topics.
  • Comprehensive fact-finding: Maximizes recall to ensure no critical information is missed.
  • User-friendly interface: Enables easy reconciliation of generated results with ground truth evidence.
  • Report-ready format: Facilitates collaboration and analysis.

Reliant AI’s vision is to democratize access to information and accelerate decision-making across various industries. By leveraging the power of generative AI, the company aims to transform the way organizations approach data analysis and unlock new opportunities for growth and innovation.

“Information and data are a critically overlooked part of making the life sciences progress to bring about a better world. The sheer amount of menial labor involved in data-intensive industries today means that many highly skilled professionals are focused on wrangling data, rather than solving complex issues. We created an AI system that understands the life sciences to radically grow its capacity to perform research at scale,” said Karl Moritz Hermann, CEO and Co-Founder of Reliant AI.